Fate Therapeutics, Inc. FATE
Analyst Consensus
Price Objectif
Analyst historical
| Analyste | Entreprise | Prix lors de l'analyse | Prix cible | Gain potentiel | Date de publication |
|---|---|---|---|---|---|
| Etzer Darout | BMO Capital | 3.37 $ | 5 $ | 1.63 % | 13/11/2024 |
| Benjamin Burnett | Stifel Nicolaus | 3.27 $ | 5 $ | 1.73 % | 14/08/2024 |
| Edward Tenthoff | Piper Sandler | 3.605 $ | 6 $ | 2.40 % | 17/06/2024 |
| Debjit Chattopadhyay | H.C. Wainwright | 4.24 $ | 5 $ | 0.76 % | 16/05/2024 |
| Edward Tenthoff | Piper Sandler | 3.88 $ | 4 $ | 0.12 % | 10/05/2024 |
| Etzer Darout | BMO Capital | 3.865 $ | 6 $ | 2.14 % | 10/05/2024 |
| Bill Maughan | Canaccord Genuity | 3.9 $ | 9 $ | 5.10 % | 10/05/2024 |
| Robyn Karnauskas | Truist Financial | 11 $ | 7 $ | -4.00 % | 05/01/2023 |
| Andrea Tan | Goldman Sachs | 15.37 $ | 10 $ | -5.37 % | 15/12/2022 |
| Matthew Biegler | Oppenheimer | 48.98 $ | 135 $ | 86.02 % | 13/12/2021 |
| Yigal Nochomovitz | Citigroup | 60.79 $ | 87 $ | 26.21 % | 08/11/2021 |
| Anthony Butler | Roth Capital | 61.42 $ | 60 $ | -1.42 % | 05/11/2021 |
| Michael Yee | Jefferies | 58.16 $ | 145 $ | 86.84 % | 25/10/2021 |
| Edward Tenthoff | Piper Sandler | 67.01 $ | 113 $ | 45.99 % | 20/08/2021 |